Opus Genetics, Inc. 8-K

What Happened
Opus Genetics, Inc. (IRD) filed an 8-K disclosing that on April 2, 2026 it entered a senior secured Note Purchase Agreement with OPCM SA LLC (as Purchaser Agent) and certain purchasers for up to $155 million of senior secured notes (Purchasers committed $105M; $50M uncommitted). The company also entered a Stock Purchase and Conversion Agreement to sell 1,116,070 shares of common stock at $4.48 per share for $4,999,994. An initial $35M tranche is expected to fund at the initial closing (effective date expected April 20, 2026). A press release was issued April 6, 2026.

Key Details

• Total facility: up to $155 million (Purchasers committed $105M; $50M uncommitted in two $25M tranches available subject to approvals).
• Tranches/timing: $35M initial tranche (expected April 20, 2026); second $35M optional until April 2, 2027; $25M third tranche conditioned on FDA Application Acceptance for OPGx-LCA5 by March 31, 2028; $10M fourth tranche tied to FDA approval or purchaser option by March 31, 2028.
• Terms: Notes mature April 2, 2033; interest = 3-month Term SOFR + margin (3.68% floor); first eight interest payments are 50% paid-in-kind and 50% cash, then 100% cash. Principal: 50% of outstanding principal due on the sixth anniversary of the First Purchase Date, remainder at maturity.
• Equity and conversion features: Purchasers will receive 1,116,070 purchase shares at $4.48 each ($4,999,994) and may convert up to 10% of their outstanding note principal into common stock at $6.72/share within 18 months of the effective date. The agreement includes an option to issue additional nominal-priced shares to protect purchasers in a dilutive equity round.
• Security and covenants: Obligations are guaranteed by certain subsidiaries and secured by a pledge of equity interests and substantially all tangible and intangible assets; agreement includes customary covenants, default remedies and prepayment provisions.

Why It Matters
This financing provides Opus Genetics with immediate liquidity (an initial $35M plus committed tranches) and contingent future funding tied to clinical and regulatory milestones for OPGx-LCA5, which can extend the company’s runway. The notes are secured and include covenants that may limit flexibility (e.g., restrictions on indebtedness, liens and dispositions). There is potential dilution from the equity sale and from note conversions (conversion price $6.72/share and an equity issuance of ~1.12M shares), and initial interest payments are partially paid-in-kind, reducing near-term cash interest outflows. Investors should note the maturity profile (2033) and the material securing and covenant terms that accompany the financing.